HEADER APOPTOSIS 21-JAN-21 7LHB
TITLE CRYSTAL STRUCTURE OF BCL-2 IN COMPLEX WITH PRODRUG ABBV-167
COMPND MOL_ID: 1;
COMPND 2 MOLECULE: APOPTOSIS REGULATOR BCL-2;
COMPND 3 CHAIN: A, B, C;
COMPND 4 FRAGMENT: UNP RESIDUES 35-91 REPLACED WITH DVEENRTEAPEGTESE;
COMPND 5 ENGINEERED: YES;
COMPND 6 MUTATION: YES
SOURCE MOL_ID: 1;
SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS, SYNTHETIC CONSTRUCT;
SOURCE 3 ORGANISM_COMMON: HUMAN;
SOURCE 4 ORGANISM_TAXID: 9606, 32630;
SOURCE 5 GENE: BCL2;
SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3);
SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008
KEYWDS BCL-2, APOPTOSIS, PRODRUG, ABBV-167
EXPDTA X-RAY DIFFRACTION
AUTHOR R.A.JUDGE,A.H.SALEM
REVDAT 4 18-OCT-23 7LHB 1 REMARK
REVDAT 3 13-APR-22 7LHB 1 COMPND FORMUL
REVDAT 2 16-JUN-21 7LHB 1 JRNL
REVDAT 1 14-APR-21 7LHB 0
JRNL AUTH A.H.SALEM,Z.F.TAO,O.F.BUENO,J.CHEN,S.CHEN,R.EDALJI,
JRNL AUTH 2 S.W.ELMORE,K.M.FOURNIER,K.C.HARPER,R.HONG,G.J.JENKINS,J.JI,
JRNL AUTH 3 R.A.JUDGE,J.C.KALVASS,R.C.KLIX,Y.Y.KU,J.D.LEVERSON,
JRNL AUTH 4 R.A.MARKS,K.C.MARSH,R.M.MENON,C.H.PARK,D.C.PHILLIPS,Y.M.PU,
JRNL AUTH 5 S.H.ROSENBERG,Y.D.SANZGIRI,A.Y.SHEIKH,Y.SHI,D.STOLARIK,
JRNL AUTH 6 A.A.SULEIMAN,X.WANG,G.G.Z.ZHANG,N.D.CATRON,A.J.SOUERS
JRNL TITL EXPANDING THE REPERTOIRE FOR "LARGE SMALL MOLECULES":
JRNL TITL 2 PRODRUG ABBV-167 EFFICIENTLY CONVERTS TO VENETOCLAX WITH
JRNL TITL 3 REDUCED FOOD EFFECT IN HEALTHY VOLUNTEERS.
JRNL REF MOL.CANCER THER. V. 20 999 2021
JRNL REFN ESSN 1538-8514
JRNL PMID 33785651
JRNL DOI 10.1158/1535-7163.MCT-21-0077
REMARK 2
REMARK 2 RESOLUTION. 2.07 ANGSTROMS.
REMARK 3
REMARK 3 REFINEMENT.
REMARK 3 PROGRAM : BUSTER 2.11.7
REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER,
REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN,
REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD
REMARK 3
REMARK 3 DATA USED IN REFINEMENT.
REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.07
REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 60.61
REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL
REMARK 3 COMPLETENESS FOR RANGE (%) : 99.5
REMARK 3 NUMBER OF REFLECTIONS : 32544
REMARK 3
REMARK 3 FIT TO DATA USED IN REFINEMENT.
REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT
REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM
REMARK 3 R VALUE (WORKING + TEST SET) : 0.204
REMARK 3 R VALUE (WORKING SET) : 0.203
REMARK 3 FREE R VALUE : 0.238
REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL
REMARK 3 FREE R VALUE TEST SET COUNT : 1607
REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL
REMARK 3
REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN.
REMARK 3 TOTAL NUMBER OF BINS USED : NULL
REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.07
REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.08
REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.68
REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : NULL
REMARK 3 BIN R VALUE (WORKING + TEST SET) : NULL
REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL
REMARK 3 BIN R VALUE (WORKING SET) : 0.2689
REMARK 3 BIN FREE R VALUE : 0.3325
REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL
REMARK 3 BIN FREE R VALUE TEST SET COUNT : 38
REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL
REMARK 3
REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT.
REMARK 3 PROTEIN ATOMS : 3383
REMARK 3 NUCLEIC ACID ATOMS : 0
REMARK 3 HETEROGEN ATOMS : 201
REMARK 3 SOLVENT ATOMS : 205
REMARK 3
REMARK 3 B VALUES.
REMARK 3 FROM WILSON PLOT (A**2) : NULL
REMARK 3 MEAN B VALUE (OVERALL, A**2) : 51.33
REMARK 3 OVERALL ANISOTROPIC B VALUE.
REMARK 3 B11 (A**2) : -19.31370
REMARK 3 B22 (A**2) : 9.92660
REMARK 3 B33 (A**2) : 9.38710
REMARK 3 B12 (A**2) : 0.00000
REMARK 3 B13 (A**2) : -11.40270
REMARK 3 B23 (A**2) : 0.00000
REMARK 3
REMARK 3 ESTIMATED COORDINATE ERROR.
REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.310
REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.197
REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.167
REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.195
REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.167
REMARK 3
REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797
REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601
REMARK 3
REMARK 3 CORRELATION COEFFICIENTS.
REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.915
REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.910
REMARK 3
REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15
REMARK 3 TERM COUNT WEIGHT FUNCTION.
REMARK 3 BOND LENGTHS : 3699 ; 2.000 ; HARMONIC
REMARK 3 BOND ANGLES : 5026 ; 2.000 ; HARMONIC
REMARK 3 TORSION ANGLES : 1306 ; 2.000 ; SINUSOIDAL
REMARK 3 TRIGONAL CARBON PLANES : NULL ; NULL ; NULL
REMARK 3 GENERAL PLANES : 737 ; 5.000 ; HARMONIC
REMARK 3 ISOTROPIC THERMAL FACTORS : 3699 ; 10.000 ; HARMONIC
REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL
REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL
REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL
REMARK 3 CHIRAL IMPROPER TORSION : 407 ; 5.000 ; SEMIHARMONIC
REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL
REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL
REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL
REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL
REMARK 3 IDEAL-DIST CONTACT TERM : 3137 ; 4.000 ; SEMIHARMONIC
REMARK 3
REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES.
REMARK 3 BOND LENGTHS (A) : 0.008
REMARK 3 BOND ANGLES (DEGREES) : 0.81
REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 2.98
REMARK 3 OTHER TORSION ANGLES (DEGREES) : 16.71
REMARK 3
REMARK 3 TLS DETAILS
REMARK 3 NUMBER OF TLS GROUPS : NULL
REMARK 3
REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4
REMARK 4 7LHB COMPLIES WITH FORMAT V. 3.30, 13-JUL-11
REMARK 100
REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 22-JAN-21.
REMARK 100 THE DEPOSITION ID IS D_1000254083.
REMARK 200
REMARK 200 EXPERIMENTAL DETAILS
REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION
REMARK 200 DATE OF DATA COLLECTION : 09-AUG-10
REMARK 200 TEMPERATURE (KELVIN) : 100
REMARK 200 PH : 8.0
REMARK 200 NUMBER OF CRYSTALS USED : 1
REMARK 200
REMARK 200 SYNCHROTRON (Y/N) : Y
REMARK 200 RADIATION SOURCE : APS
REMARK 200 BEAMLINE : 17-ID
REMARK 200 X-RAY GENERATOR MODEL : NULL
REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M
REMARK 200 WAVELENGTH OR RANGE (A) : 1.000
REMARK 200 MONOCHROMATOR : NULL
REMARK 200 OPTICS : NULL
REMARK 200
REMARK 200 DETECTOR TYPE : CCD
REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210
REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS BUILT 20191015
REMARK 200 DATA SCALING SOFTWARE : XDS
REMARK 200
REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 32544
REMARK 200 RESOLUTION RANGE HIGH (A) : 2.068
REMARK 200 RESOLUTION RANGE LOW (A) : 60.610
REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL
REMARK 200
REMARK 200 OVERALL.
REMARK 200 COMPLETENESS FOR RANGE (%) : 99.5
REMARK 200 DATA REDUNDANCY : 3.400
REMARK 200 R MERGE (I) : 0.05400
REMARK 200 R SYM (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 12.9000
REMARK 200
REMARK 200 IN THE HIGHEST RESOLUTION SHELL.
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.07
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.10
REMARK 200 COMPLETENESS FOR SHELL (%) : NULL
REMARK 200 DATA REDUNDANCY IN SHELL : NULL
REMARK 200 R MERGE FOR SHELL (I) : NULL
REMARK 200 R SYM FOR SHELL (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL
REMARK 200
REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH
REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT
REMARK 200 SOFTWARE USED: MOLREP
REMARK 200 STARTING MODEL: PDB ENTRY 4LVT
REMARK 200
REMARK 200 REMARK: NULL
REMARK 280
REMARK 280 CRYSTAL
REMARK 280 SOLVENT CONTENT, VS (%): 46.66
REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.31
REMARK 280
REMARK 280 CRYSTALLIZATION CONDITIONS: 20% W/V PEG4000, 0.1 M TRIS-HCL, PH
REMARK 280 8.0, 0.2 M CALCIUM CHLORIDE, VAPOR DIFFUSION, HANGING DROP,
REMARK 280 TEMPERATURE 277K
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY
REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1
REMARK 290
REMARK 290 SYMOP SYMMETRY
REMARK 290 NNNMMM OPERATOR
REMARK 290 1555 X,Y,Z
REMARK 290 2555 -X,Y+1/2,-Z
REMARK 290
REMARK 290 WHERE NNN -> OPERATOR NUMBER
REMARK 290 MMM -> TRANSLATION VECTOR
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS
REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM
REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY
REMARK 290 RELATED MOLECULES.
REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000
REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000
REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 24.72400
REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000
REMARK 290
REMARK 290 REMARK: NULL
REMARK 300
REMARK 300 BIOMOLECULE: 1, 2, 3
REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM
REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN
REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON
REMARK 300 BURIED SURFACE AREA.
REMARK 350
REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN
REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE
REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS
REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND
REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN.
REMARK 350
REMARK 350 BIOMOLECULE: 1
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC
REMARK 350 APPLY THE FOLLOWING TO CHAINS: A
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 350
REMARK 350 BIOMOLECULE: 2
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC
REMARK 350 APPLY THE FOLLOWING TO CHAINS: B
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 350
REMARK 350 BIOMOLECULE: 3
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC
REMARK 350 APPLY THE FOLLOWING TO CHAINS: C
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 465
REMARK 465 MISSING RESIDUES
REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE
REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN
REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.)
REMARK 465
REMARK 465 M RES C SSSEQI
REMARK 465 MET A 1
REMARK 465 ALA A 2
REMARK 465 HIS A 3
REMARK 465 PRO A 4
REMARK 465 GLY A 5
REMARK 465 ARG A 6
REMARK 465 THR A 7
REMARK 465 GLY A 8
REMARK 465 ASP A 72
REMARK 465 ALA A 73
REMARK 465 GLY A 74
REMARK 465 ASP A 75
REMARK 465 ASP A 76
REMARK 465 VAL A 77
REMARK 465 GLU A 78
REMARK 465 GLU A 79
REMARK 465 ASN A 80
REMARK 465 ARG A 81
REMARK 465 THR A 82
REMARK 465 GLU A 83
REMARK 465 ALA A 84
REMARK 465 PRO A 85
REMARK 465 GLU A 86
REMARK 465 GLY A 87
REMARK 465 THR A 88
REMARK 465 GLU A 89
REMARK 465 SER A 205
REMARK 465 MET A 206
REMARK 465 ARG A 207
REMARK 465 MET B 1
REMARK 465 ALA B 2
REMARK 465 HIS B 3
REMARK 465 PRO B 4
REMARK 465 GLY B 5
REMARK 465 ARG B 6
REMARK 465 THR B 7
REMARK 465 GLY B 8
REMARK 465 ASP B 72
REMARK 465 ALA B 73
REMARK 465 GLY B 74
REMARK 465 ASP B 75
REMARK 465 ASP B 76
REMARK 465 VAL B 77
REMARK 465 GLU B 78
REMARK 465 GLU B 79
REMARK 465 ASN B 80
REMARK 465 ARG B 81
REMARK 465 THR B 82
REMARK 465 GLU B 83
REMARK 465 ALA B 84
REMARK 465 PRO B 85
REMARK 465 GLU B 86
REMARK 465 GLY B 87
REMARK 465 THR B 88
REMARK 465 GLU B 89
REMARK 465 SER B 90
REMARK 465 SER B 205
REMARK 465 MET B 206
REMARK 465 ARG B 207
REMARK 465 MET C 1
REMARK 465 ALA C 2
REMARK 465 HIS C 3
REMARK 465 PRO C 4
REMARK 465 GLY C 5
REMARK 465 ARG C 6
REMARK 465 THR C 7
REMARK 465 GLY C 8
REMARK 465 TYR C 9
REMARK 465 ASP C 72
REMARK 465 ALA C 73
REMARK 465 GLY C 74
REMARK 465 ASP C 75
REMARK 465 ASP C 76
REMARK 465 VAL C 77
REMARK 465 GLU C 78
REMARK 465 GLU C 79
REMARK 465 ASN C 80
REMARK 465 ARG C 81
REMARK 465 THR C 82
REMARK 465 GLU C 83
REMARK 465 ALA C 84
REMARK 465 PRO C 85
REMARK 465 GLU C 86
REMARK 465 GLY C 87
REMARK 465 THR C 88
REMARK 465 GLU C 89
REMARK 465 SER C 90
REMARK 465 GLU C 91
REMARK 465 VAL C 92
REMARK 465 VAL C 93
REMARK 465 GLY C 203
REMARK 465 PRO C 204
REMARK 465 SER C 205
REMARK 465 MET C 206
REMARK 465 ARG C 207
REMARK 800
REMARK 800 SITE
REMARK 800 SITE_IDENTIFIER: AC1
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: binding site for residue XZD A 4000
REMARK 800
REMARK 800 SITE_IDENTIFIER: AC2
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: binding site for residue XZD B 4000
REMARK 800
REMARK 800 SITE_IDENTIFIER: AC3
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: binding site for residue XZD C 4000
DBREF 7LHB A 1 75 UNP P10415 BCL2_HUMAN 1 34
DBREF 7LHB A 76 91 PDB 7LHB 7LHB 76 91
DBREF 7LHB A 92 207 UNP P10415 BCL2_HUMAN 92 207
DBREF 7LHB B 1 75 UNP P10415 BCL2_HUMAN 1 34
DBREF 7LHB B 76 91 PDB 7LHB 7LHB 76 91
DBREF 7LHB B 92 207 UNP P10415 BCL2_HUMAN 92 207
DBREF 7LHB C 1 75 UNP P10415 BCL2_HUMAN 1 34
DBREF 7LHB C 76 91 PDB 7LHB 7LHB 76 91
DBREF 7LHB C 92 207 UNP P10415 BCL2_HUMAN 92 207
SEQADV 7LHB PRO A 4 UNP P10415 ALA 4 ENGINEERED MUTATION
SEQADV 7LHB LYS A 26 UNP P10415 ARG 26 ENGINEERED MUTATION
SEQADV 7LHB PRO B 4 UNP P10415 ALA 4 ENGINEERED MUTATION
SEQADV 7LHB LYS B 26 UNP P10415 ARG 26 ENGINEERED MUTATION
SEQADV 7LHB PRO C 4 UNP P10415 ALA 4 ENGINEERED MUTATION
SEQADV 7LHB LYS C 26 UNP P10415 ARG 26 ENGINEERED MUTATION
SEQRES 1 A 166 MET ALA HIS PRO GLY ARG THR GLY TYR ASP ASN ARG GLU
SEQRES 2 A 166 ILE VAL MET LYS TYR ILE HIS TYR LYS LEU SER GLN LYS
SEQRES 3 A 166 GLY TYR GLU TRP ASP ALA GLY ASP ASP VAL GLU GLU ASN
SEQRES 4 A 166 ARG THR GLU ALA PRO GLU GLY THR GLU SER GLU VAL VAL
SEQRES 5 A 166 HIS LEU THR LEU ARG GLN ALA GLY ASP ASP PHE SER ARG
SEQRES 6 A 166 ARG TYR ARG ARG ASP PHE ALA GLU MET SER SER GLN LEU
SEQRES 7 A 166 HIS LEU THR PRO PHE THR ALA ARG GLY ARG PHE ALA THR
SEQRES 8 A 166 VAL VAL GLU GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY
SEQRES 9 A 166 ARG ILE VAL ALA PHE PHE GLU PHE GLY GLY VAL MET CYS
SEQRES 10 A 166 VAL GLU SER VAL ASN ARG GLU MET SER PRO LEU VAL ASP
SEQRES 11 A 166 ASN ILE ALA LEU TRP MET THR GLU TYR LEU ASN ARG HIS
SEQRES 12 A 166 LEU HIS THR TRP ILE GLN ASP ASN GLY GLY TRP ASP ALA
SEQRES 13 A 166 PHE VAL GLU LEU TYR GLY PRO SER MET ARG
SEQRES 1 B 166 MET ALA HIS PRO GLY ARG THR GLY TYR ASP ASN ARG GLU
SEQRES 2 B 166 ILE VAL MET LYS TYR ILE HIS TYR LYS LEU SER GLN LYS
SEQRES 3 B 166 GLY TYR GLU TRP ASP ALA GLY ASP ASP VAL GLU GLU ASN
SEQRES 4 B 166 ARG THR GLU ALA PRO GLU GLY THR GLU SER GLU VAL VAL
SEQRES 5 B 166 HIS LEU THR LEU ARG GLN ALA GLY ASP ASP PHE SER ARG
SEQRES 6 B 166 ARG TYR ARG ARG ASP PHE ALA GLU MET SER SER GLN LEU
SEQRES 7 B 166 HIS LEU THR PRO PHE THR ALA ARG GLY ARG PHE ALA THR
SEQRES 8 B 166 VAL VAL GLU GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY
SEQRES 9 B 166 ARG ILE VAL ALA PHE PHE GLU PHE GLY GLY VAL MET CYS
SEQRES 10 B 166 VAL GLU SER VAL ASN ARG GLU MET SER PRO LEU VAL ASP
SEQRES 11 B 166 ASN ILE ALA LEU TRP MET THR GLU TYR LEU ASN ARG HIS
SEQRES 12 B 166 LEU HIS THR TRP ILE GLN ASP ASN GLY GLY TRP ASP ALA
SEQRES 13 B 166 PHE VAL GLU LEU TYR GLY PRO SER MET ARG
SEQRES 1 C 166 MET ALA HIS PRO GLY ARG THR GLY TYR ASP ASN ARG GLU
SEQRES 2 C 166 ILE VAL MET LYS TYR ILE HIS TYR LYS LEU SER GLN LYS
SEQRES 3 C 166 GLY TYR GLU TRP ASP ALA GLY ASP ASP VAL GLU GLU ASN
SEQRES 4 C 166 ARG THR GLU ALA PRO GLU GLY THR GLU SER GLU VAL VAL
SEQRES 5 C 166 HIS LEU THR LEU ARG GLN ALA GLY ASP ASP PHE SER ARG
SEQRES 6 C 166 ARG TYR ARG ARG ASP PHE ALA GLU MET SER SER GLN LEU
SEQRES 7 C 166 HIS LEU THR PRO PHE THR ALA ARG GLY ARG PHE ALA THR
SEQRES 8 C 166 VAL VAL GLU GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY
SEQRES 9 C 166 ARG ILE VAL ALA PHE PHE GLU PHE GLY GLY VAL MET CYS
SEQRES 10 C 166 VAL GLU SER VAL ASN ARG GLU MET SER PRO LEU VAL ASP
SEQRES 11 C 166 ASN ILE ALA LEU TRP MET THR GLU TYR LEU ASN ARG HIS
SEQRES 12 C 166 LEU HIS THR TRP ILE GLN ASP ASN GLY GLY TRP ASP ALA
SEQRES 13 C 166 PHE VAL GLU LEU TYR GLY PRO SER MET ARG
HET XZD A4000 67
HET XZD B4000 67
HET XZD C4000 67
HETNAM XZD PHOSPHORIC ACID MONO-[5-(5-{4-[2-(4-CHLORO-PHENYL)-4,4-
HETNAM 2 XZD DIMETHYL-CYCLOHEX-1-ENYLMETHYL]-PIPERAZIN-1-YL}-2-{3-
HETNAM 3 XZD NITRO-4-[(TETRAHYDRO-PYRAN-4-YLMETHYL)-AMINO]-
HETNAM 4 XZD BENZENESULFONYLAMINOCARBONYL}-PHENOXY)-PYRROLO[2,3-
HETNAM 5 XZD B]PYRIDIN-7-YLMETHYL] ESTER
FORMUL 4 XZD 3(C46 H53 CL N7 O11 P S)
FORMUL 7 HOH *205(H2 O)
HELIX 1 AA1 ASP A 10 LYS A 26 1 17
HELIX 2 AA2 GLU A 91 TYR A 108 1 18
HELIX 3 AA3 TYR A 108 LEU A 119 1 12
HELIX 4 AA4 THR A 125 ARG A 139 1 15
HELIX 5 AA5 ASN A 143 ARG A 164 1 22
HELIX 6 AA6 PRO A 168 HIS A 184 1 17
HELIX 7 AA7 LEU A 185 ASN A 192 1 8
HELIX 8 AA8 GLY A 193 GLY A 203 1 11
HELIX 9 AA9 ASP B 10 LYS B 26 1 17
HELIX 10 AB1 VAL B 92 TYR B 108 1 17
HELIX 11 AB2 TYR B 108 LEU B 119 1 12
HELIX 12 AB3 THR B 125 PHE B 138 1 14
HELIX 13 AB4 ASN B 143 ARG B 164 1 22
HELIX 14 AB5 PRO B 168 LEU B 185 1 18
HELIX 15 AB6 LEU B 185 ASN B 192 1 8
HELIX 16 AB7 GLY B 193 GLY B 203 1 11
HELIX 17 AB8 ASN C 11 GLN C 25 1 15
HELIX 18 AB9 LEU C 95 TYR C 108 1 14
HELIX 19 AC1 TYR C 108 LEU C 119 1 12
HELIX 20 AC2 THR C 125 ARG C 139 1 15
HELIX 21 AC3 ASN C 143 ARG C 164 1 22
HELIX 22 AC4 PRO C 168 LEU C 185 1 18
HELIX 23 AC5 LEU C 185 ASN C 192 1 8
HELIX 24 AC6 GLY C 193 GLU C 200 1 8
SITE 1 AC1 21 ALA A 100 ASP A 103 ARG A 107 TYR A 108
SITE 2 AC1 21 ASP A 111 PHE A 112 GLU A 136 ASN A 143
SITE 3 AC1 21 TRP A 144 GLY A 145 VAL A 148 ALA A 149
SITE 4 AC1 21 GLU A 152 PHE A 153 VAL A 156 PHE A 198
SITE 5 AC1 21 TYR A 202 HOH A4101 HOH A4115 HOH A4151
SITE 6 AC1 21 ARG B 109
SITE 1 AC2 19 ALA B 100 ASP B 103 PHE B 104 ARG B 107
SITE 2 AC2 19 TYR B 108 GLU B 136 LEU B 137 ASN B 143
SITE 3 AC2 19 TRP B 144 GLY B 145 VAL B 148 ALA B 149
SITE 4 AC2 19 GLU B 152 PHE B 153 PHE B 198 TYR B 202
SITE 5 AC2 19 HOH B4101 HOH B4120 HOH B4153
SITE 1 AC3 19 ALA C 100 ASP C 103 ARG C 107 TYR C 108
SITE 2 AC3 19 ASP C 111 PHE C 112 MET C 115 GLU C 136
SITE 3 AC3 19 LEU C 137 ASN C 143 TRP C 144 GLY C 145
SITE 4 AC3 19 ARG C 146 VAL C 148 ALA C 149 PHE C 198
SITE 5 AC3 19 TYR C 202 HOH C4121 HOH C4125
CRYST1 62.362 49.448 89.359 90.00 103.63 90.00 P 1 21 1 6
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.016035 0.000000 0.003888 0.00000
SCALE2 0.000000 0.020223 0.000000 0.00000
SCALE3 0.000000 0.000000 0.011515 0.00000